Molecular genetic analysis of cystic fibrosis (CF) is routinely performed in hundreds of laboratories worldwide. The Orphanet database (www.orpha.net) lists 302 CF diagnostic laboratories (44 for Germany). Most laboratories use commercial kits that are expected to be robust and deliver reliable results. For most European populations, CFTR mutation detection rates of 70 -90% can be achieved by testing the most frequent mutations (which are mainly included in commercial kits), thereby identifying homozygosity or compound heterozygosity for CFTR mutations in approximately 50 -80% of CF patients. Very often, the referring clinicians (mostly paediatricians or geneticists) request testing of only the CF patients and not of their parents. At the Institute of Human Genetics in Hannover, we have tested 2168 patients with the clinical diagnosis of CF, but we have received samples only from the parents (mostly after having tested the index patients) in 198 (9.1%) of these cases. However, as again stated in the best practice guidelines for molecular genetic analysis of CFand CFTR-related disorders in the European Journal of Human Genetics, 'identification of mutation(s) on both parental alleles is required to confirm the diagnosis. Homozygous and compound heterozygous status should thus be confirmed by studying the parents'. 1 Here, we present two recent cases from our laboratories that strengthen the need to correctly assign the parental alleles, particularly in the context of prenatal diagnosis of CF or carrier testing. Figure S2 ). Thus, in both cases, the initial test results (homozygosity for F508del) had to be revised after testing the parents.
Homozygosity for F508del is the most frequent genotype of CF patients. Therefore, the initial test results were completely unremarkable until the later problems were found. Several scenarios are imaginable, in which testing for F508del only could lead to erroneous conclusions in case of prenatal diagnosis or carrier testing. In family 1, an F508del/1677delTA compound heterozygous (affected) fetus could have been misdiagnosed as an F508del heterozygous (healthy) fetus. Carrier testing of relatives of the mothers from both cases could have resulted in the erroneous exclusion of carriership.
Case 1 also illustrates that genotyping with commercial kits does not always guarantee correct results. In this case, we failed to amplify the non-F508del allele by using the allele-specific amplification technology (Elucigene kits), although the reverse hybridization line probe assay (INNO-LIPA kit) and the oligo-ligation assay (OLA, Abbott kit) correctly identified the presence of one non-F508del allele.
As F508del (22%) and 1677delTA (4.5%) are the most and second most frequent mutations in the Turkish population, respectively, 3 compound heterozygosity for these two CFTR mutations is assumed to occur relatively frequently among Turkish CF patients. As long as commercial kits do not test for 1677delTA, we recommend testing Turkish patients for this mutation with an additional test method such as PCR and PAGE or sequencing.
Companies usually optimize their panels for American and western European populations, and the sensitivity of the test is therefore lower in certain regions, notably central, southern and eastern Europe. Suppliers of commercial kits should be aware of possible genotyping problems and should take care to solve these problems. From the annual external quality assessment scheme of the European CF-network (www.cfnetwork.be), it is known that other genotypes than those described above caused genotyping errors with commercial kits, that is, compound heterozygosity for W1282X and S1251N was mistyped as homozygosity for W1282X (OLA), and R553X/G551D compound samples appeared as homozygous for R553X and heterozygous for G551D (reverse hybridization line probe assay). By changing the assay and/or disclaimers on the instruction manuals, both companies (Abbott and Innogenetics) reacted to solve these problems. We conclude that although commercial CFTR kits may usually be robust and reliable, they cannot guarantee correct results for all possible combinations of mutations. As highly recommended in European Figure S1 shows all test results. 
